Search the Newsreel

Balchem Corp (BCPC) Earnings Forecast: Future EPS & Revenue Growth Estimates

Balchem (BCPC) Could Be 16% Undervalued As Q2 Results And Buybacks Land

Balchem (BCPC) recently released its Q2 2026 results and provided an update on its share buyback program. The stock is considered 16% undervalued, with a fair value estimated at $207 compared to its current price of $174.78, driven by its new microencapsulation facility and …

H.C. Wainwright raises Balchem stock price target on strong earnings

H.C. Wainwright has increased its price target for Balchem (NASDAQ:BCPC) to $215 from $190, reiterating a Buy rating, following the company's strong second-quarter 2026 financial results. Balchem reported revenue of $284 million, exceeding estimates, and GAAP net earnings of $1.39 per diluted share, also …

Balchem (BCPC) Stock Gains Look Muted Next To Record Margins

Balchem (BCPC) reported record quarterly revenue and adjusted earnings, yet its stock only saw a 3% gain. The company's net profit margin is up, and it achieved record adjusted EBITDA, indicating strong profitability trends. Despite a high 34.1x P/E ratio, the earnings quality suggests …

Balchem Corporation Revenue Breakdown – NASDAQ:BCPC

Balchem Corporation (BCPC) generated $1.04 billion USD in revenue last year, with its Human Nutrition and Health segment being the top performer at $659.39 million USD. The United States was the largest contributor to revenue, accounting for $759.45 million USD. These figures highlight the …

Balchem (BCPC) Stock Trades At A Discount On Cash Flow And A Premium On Earnings

Balchem: It's A Buy From Me After Posting Strong Q2 Results

Q2 2026 Balchem Corp Earnings Call Transcript

Balchem Corp reported record consolidated sales of $284 million, up 11.2% year-over-year, and record adjusted EBITDA of $78 million for Q2 2026. The growth was broad-based across all segments, including significant gains in Animal Nutrition & Health and Specialty Products, while Human Nutrition & …

Balchem Corporation Reports Record Second Quarter 2026 Net Sales, Earnings and Adjusted EBITDA

Balchem Corporation announced record financial results for the second quarter of 2026, with net sales increasing 11.2% to $284.0 million, net earnings rising 16.6% to $44.6 million, and adjusted EBITDA growing 12.6% to $77.9 million. This strong performance was driven by growth across all …

Balchem Q2 2026: Revenue Hits $284.0M, Up 11% Year-Over-Year

Balchem Corporation (NASDAQ: BCPC) reported strong Q2 2026 results, with adjusted earnings of $1.49 per share beating estimates and revenue reaching $284.0 million, an 11.2% increase year-over-year. The Human Nutrition and Health segment was a key driver, contributing $176.9 million in revenue with 10.0% …

Balchem Releases Q2 2026 Financial Results

Balchem Corporation reported strong Q2 2026 financial results, exceeding consensus estimates with adjusted earnings of $1.49 per share and revenue of $284.0 million. The company saw significant growth in its Human Nutrition and Health segment, driven by robust demand for its specialty ingredients. Analysts …

Balchem Reports Q2 2026: Revenue $284.0M, Net Earnings $44.6M, Adjusted EPS $1.49

Balchem reported record financial results for the second quarter of fiscal year 2026, with net sales reaching $284.0 million, an 11.2% increase year-over-year. The company achieved GAAP net earnings of $44.6 million and an adjusted diluted EPS of $1.49. Balchem also generated $36.2 million …

Earnings Flash (BCPC) Balchem Corporation Posts Q2 Adjusted EPS $1.49 per Share, Vs. FactSet Est of $1.40

Balchem Corporation (BCPC) reported strong Q2 adjusted earnings per share of $1.49, surpassing the FactSet estimate of $1.40. This announcement provides key financial data for investors and analysts tracking the company's performance. The detailed earnings flash highlights the company's profitability during the quarter.

Balchem Corporation 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:BCPC) 2026-07-31

Balchem Corp reported record consolidated sales of $284 million, up 11.2% year-over-year, and record adjusted EBITDA of $78 million for Q2 2026. The growth was broad-based across all segments, including significant gains in Animal Nutrition & Health and Specialty Products, while Human Nutrition & …

ETFs Investing in Balchem Corp Stocks

This article lists various ETFs that include Balchem Corp (BL9B) stocks in their holdings. The information provided for each ETF includes market value, weight, issuer, management style, focus, expense ratio, assets under management (AUM), current price and change, relative volume, and 3-year NAV total …

Balchem Corp (BCPC) Financial Health: Profitability & Balance Sheet Analysis

Balchem Corp (BCPC) has a robust financial score of 9.04, ranking 6th out of 65 in the Chemicals industry, indicating strong financial health and high operating efficiency. The company recently reported a quarterly revenue of $270.71 million, an 8.06% year-over-year increase, with net profit …

BALCHEM CORP 2026: Revenue $284M, EPS $1.39— 10-Q Summary

BALCHEM CORP (BCPC) reported strong second-quarter 2026 results with revenue of $284 million, net income of $44.62 million, and diluted EPS of $1.39, all surpassing prior-year figures. This growth was broad-based across all segments, driven by increased volume, improved mix, and higher selling prices, …

Balchem Number of Employees 2026 | Employee Count & Headcount Data

Balchem Corp. (BCPC) had approximately 1,353 employees worldwide as of March 2026, a 2.4% growth from 2023. The company is actively hiring with 107 active job postings in 2026 and its workforce is concentrated in the United States, followed by Italy and Norway. While …

Balchem Corp (BCPC) Institutional Confidence

This article analyzes Balchem Corp's (BCPC) institutional confidence score, reporting it at 7.00, which ranks 28th out of 65 in the Chemicals industry. The institutional shareholding proportion is 88.34%, marking a quarter-over-quarter decrease of 4.74%. The largest institutional shareholder, ETHSX, significantly increased its holdings …

How Balchem Corporation (BCPC) Affects Rotational Strategy Timing

Balchem Corporation (BCPC) is exhibiting a mid-channel oscillation pattern with strong near-term sentiment but neutral mid and long-term outlooks. AI models have generated three distinct trading strategies: a position trading strategy, a momentum breakout strategy, and a risk hedging strategy, each tailored to different …

Balchem Corporation (NASDAQ: BCPC) boosts revolving credit to $650M and 2031

Balchem Corporation amended its credit agreement on July 24, 2026, increasing its revolving commitment from $550 million to $650 million and extending the maturity date to July 24, 2031. The amendment also allows foreign subsidiary Balchem B.V. to borrow, eliminates a 10 basis point …

Balchem Corp (BCPC) Cash Flow

This article provides a detailed cash flow statement for Balchem Corp (BCPC), broken down by quarterly and annual periods. It covers operating, investing, and financing cash flows, along with related metrics like net income and capital expenditures. The report also includes an FAQ section …

Balchem (BCPC) Q2 2026 Preview: EPS Est. $1.43, Reports July 31

Balchem Corporation (BCPC) is expected to report Q2 2026 earnings per share of $1.43 on revenue of $268.5 million on July 31, according to two analysts. This represents a 12.6% increase in EPS and 5.1% growth in revenue year-over-year. Investors will be closely watching …

Balchem Ups Revolving Credit Facility to $650 Million and Extends Maturity to 2031 With JPMorgan

Balchem recently amended its credit facility, increasing its revolving commitments to $650 million and extending the maturity date to July 24, 2031. This amendment, facilitated with JPMorgan Chase and a syndicate of lenders, also allows foreign subsidiary borrowing, removes a SOFR adjustment, and reduces …

TradingKey

This article provides a detailed historical income statement for Balchem Corp (BCPC), displaying quarterly and annual data from FY2012Q1 through FY2026Q1. It includes various financial metrics such as total revenue, cost of revenue, operating expenses, operating profit, income before tax, net income, and earnings …

BCPC|Balchem Corp|Price:162.810|Chg%:+1.810

This article provides a detailed analysis of Balchem Corp (BCPC), highlighting its strong fundamentals, high growth potential, and fair valuation within the Chemicals industry. It notes a high institutional ownership and suggests the stock is suitable for range-bound swing trading due to its sideways …

Balchem Corp Revenue Breakdown – BIVA:BCPC

This article provides a revenue breakdown for Balchem Corp (BCPC), highlighting its top-performing segment and geographical contribution. Last year, the company generated 18.70 billion Mexican Pesos (MXN) in total revenue, with Human Nutrition and Health contributing 11.89 billion MXN, and the United States being …

Vitamin K2 Market Projected to Reach $339.9 million by 2031 | Top Companies are Gnosis by Lesaffre (France) and Balchem Corp (US)

The Vitamin K2 market is forecast to grow from USD 179.0 million in 2026 to USD 339.9 million by 2031, at a CAGR of 13.7%. This growth is driven by increasing consumer awareness regarding its benefits for bone and cardiovascular health, coupled with a …

Balchem Corp (BCPC) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Balchem Corp (BCPC), noting its current valuation score of 6.27, which ranks 62 out of 65 in the Chemicals industry. The P/E ratio is currently 33.10. The article also indicates that relevant data for P/B, P/S, and …

Balchem Corporation (BCPC) Stock Forecasts

This article provides a stock forecast for Balchem Corporation (BCPC), noting that Argus has lowered its target price to $148.00. Balchem Corp is described as a company that develops, manufactures, and markets specialty performance ingredients and products for various industries. The report also highlights …

Balchem (BCPC) Q3 2024 Earnings Report - Results, Call & Slides

Balchem (BCPC) reported its Q3 2024 earnings, missing both EPS and revenue expectations. The company posted an actual EPS of $18.03 against a consensus of $19.52, and actual revenue of $4.20 billion compared to an expected $4.24 billion, though revenue did show a 4.35% …

Balchem earnings up next: Can specialty ingredients sustain growth?

Balchem Corporation is set to release its second-quarter earnings, with analysts anticipating a sequential dip from its strong first-quarter performance. Investors will be closely watching whether the company can maintain momentum in its core human and animal nutrition segments, particularly focusing on margin sustainability …

Enterprise value to EBIT forward of Balchem Corp – BX:BL9B

The article focuses on the enterprise value to EBIT forward for Balchem Corp, identified by the ticker BX:BL9B on the BX Swiss exchange. It appears to be a financial data presentation or a gateway to more detailed financial information on TradingView, indicating that the …